Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 3/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636936 | 0.92 | PTGDR2 (0.36) | PTGDR2AKR1B1TBXA2RPTGDRMEN1 | |
| SCHEMBL3327098 | 0.91 | L3MBTL1 (0.35) | PTGDR2DDR1MEN1LMNAPOLB | |
| SCHEMBL4636889 | 0.86 | MEN1 (0.35) | PTGDR2AKR1B1MEN1LMNAPOLB | |
| SCHEMBL3329390 | 0.86 | CNR1 (0.38) | PTGDR2TRPV4CYP3A4KCNH2 | |
| SCHEMBL13318596 | 0.84 | LMNA (0.31) | PTGDR2LMNA | |
| SCHEMBL4635990 | 0.84 | L3MBTL1 (0.35) | PTGDR2TBXA2RPTGDRMEN1LMNA | |
| SCHEMBL4635707 | 0.82 | PTGDR2 (0.43) | PTGDR2AKR1B1MEN1LMNAPOLB | |
| SCHEMBL3324726 | 0.81 | RORC (0.34) | PTGDR2DDR1TRPV4HSD11B1RORC | |
| SCHEMBL4635659 | 0.80 | CASP6 (0.36) | PTGDR2MEN1LMNAPOLBKMT2A | |
| SCHEMBL4636980 | 0.79 | TDP1 (0.38) | PTGDR2AKR1B1MEN1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | claimed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | claimed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | claimed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | ARGENTA ORAL THERAPEUTICS LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| CN-101678009-A | Indolizine acetic acid derivatives as CRTH2 antagonists | ARGENTA DISCOVERY LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| EP-2136804-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Argenta Oral Therapeutics Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113965-A1 | INDOLIZINE ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137300-A1 | Indolizine Acetic Acid Derivatives as CRTH2 Antagonists | HRH1, HRH4, HRH2 | PTGDR2 826/4885AKR1B1 1372/4885TBXA2R 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.